SSTR2 and neoplasm: Importantly, our findings suggest that a therapeutic approach aimed to interfere with hsa-miR-5096 activity, inhibiting its targeting of SSTR2 3’-UTR sequences, would enhance SSTRs expression and sensitize tumor cells to PRRT or other SSTR-targeted therapies.